US/UK/Canada

Share

Contacts

  • General Press Enquiries
    For general press enquiries please contact the AbbVie Corporate Communications team at UKMediaRelations@abbvie.com or call us on 01628 925200
    01628 925200
    https://twitter.com/abbvieuk
    • Pick a time period -
    Tags ( Active)

    AbbVie’s SKYRIZI[®] (risankizumab) Is Recommended by NICE as an Option for Use in Adults with Moderately to Severely Active Ulcerative Colitis

    For UK consumer, medical and trade media only · In final guidance published today, adults in England and Wales with moderately to severely active ulcerative colitis (UC) who cannot tolerate, or have not responded well or lost response to conventional or biological therapy including a tumour necrosis factor (TNF)-alpha inhibitor, will have an additional treatment option.[1] · UC, a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD), is estimated to affect around 296,000 people across the UK and may lead to reduced quality of life, inability to work and disability due

    AbbVie Announces New UK Vice President and General Manager

    For UK trade and national media · Steve Hopkinson has been appointed UK Vice President and General Manager with effect from 1[st] August 2024 · An internal appointment, Steve takes on the position having held senior UK, European and Global commercial roles in his ten-year career at AbbVie · Steve succeeds Todd Manning, who was appointed in 2019Maidenhead, UK, 16 July, 2024 – AbbVie (NYSE: ABBV) AbbVie today announced that Steve Hopkinson has been appointed as Vice President and General Manager, UK. With effect from 1[st] August 2024, Steve will succeed Todd Manning, who retires

    SMC Approves First Subcutaneous Bispecific Treatment Option Tepkinly[® ]▼(epcoritamab) for Adults with an Aggressive Form of Blood Cancer After Two or More Lines of Systemic Therapy

    · For the first time, adults in Scotland with diffuse large B-cell lymphoma (DLBCL) whose cancer has returned or not responded to at least two prior treatments, will have access to a subcutaneous bispecific treatment option administered as an injection under the skin[1,2]. · Epcoritamab is part of a new class of therapies called bispecific antibodies. Bispecific antibodies help the body’s immune system to attack and destroy cancerous cells[3]. · DLBCL is an aggressive blood cancer, with approximately 430 adults diagnosed with the disease in Scotland each year. For patients whose

    AbbVie’s AQUIPTA[®]▼(atogepant) Is Recommended By NICE For The Prevention Of Migraine In Adults

    PRESS RELEASE - For UK consumer, medical and trade media only · The National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance (FDG) recommending AQUIPTA[®] (atogepant), the oral, once-daily calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) as an option in suitable patients for preventing migraine in adults who have at least 4 migraine days per month, only if at least 3 preventative treatments have not worked.[1] Suitable patients will soon have the option to be prescribed atogepant on the NHS in England and Wales. · The NICE

    AbbVie’s Produodopa® (foslevodopa-foscarbidopa) Accepted by Scottish Medicines Consortium as Treatment Option for Advanced Levodopa-Responsive Parkinson’s Disease

    For Medical and Trade media. · Foslevodopa-foscarbidopa will soon be available for eligible patients with advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia in Scotland, providing an additional option when currently available combinations of treatments have not given satisfactory results[1] · Following the recommendation by the National Institute for Health and Care Excellence (NICE) in November 2023, this means foslevodopa-foscarbidopa will soon be available for use within the NHS across the UK[2] · The advice from the

    NICE Recommends Subcutaneous Treatment Option Tepkinly[®]▼(epcoritamab) for Eligible* Adults with Aggressive Form of Blood Cancer After Two or More Lines of Systemic Therapy

    · For the first time, adults with diffuse large B-cell lymphoma (DLBCL), whose cancer has returned or not responded to at least two prior treatments, only if they have previously had polatuzumab vedotin or it is contraindicated or not tolerated, will have access to a subcutaneous bispecific treatment option administered as an injection under the skin[1,2] · Epcoritamab is part of a new class of therapies called bispecific antibodies. Bispecific antibodies help the body’s immune system to attack and destroy cancerous cells[3] · DLBCL is an aggressive blood cancer, with nearly 5,500

    MHRA Grants Conditional Marketing Authorisation for Tepkinly[®]▼(epcoritamab) as a Bispecific Treatment for Adults with Relapsed or Refractory DLBCL After Two or More Lines of Systemic Therapy

    PRESS RELEASE - For UK consumer, medical and trade media only · Diffuse large B-cell lymphoma (DLBCL) is an aggressive sub-type of non-Hodgkin’s lymphoma, with nearly 5,500 new diagnoses in the UK each year[1] · Bispecific antibodies represent a new class of therapies that work by introducing a local immune cell to a cancer cell, enabling the immune cell to attack and destroy the cancer[2]  · As the first and only subcutaneous bispecific injection, epcoritamab could offer eligible patients an additional treatment option[3] MAIDENHEAD, UK, [23 October 2023] – AbbVie (NYSE:

    AbbVie’s AQUIPTA[®]▼ (atogepant) Is Now Available In Scotland For The Prevention Of Migraines In Adults

    PRESS RELEASE - For UK consumer, medical and trade media only · The Scottish Medicines Consortium (SMC) has accepted AQUIPTA[®] (atogepant), the oral, once-daily calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for restricted use within NHS Scotland.[1] · The decision follows the Medicines and Healthcare products Regulatory Agency (MHRA) granting the marketing authorisation of atogepant in Great Britain on 30[th] August 2023 for the prophylaxis of migraine in adults who have at least four migraine days per month.[2] · Atogepant demonstrated significant reduction

    AbbVie’s AQUIPTA[®]▼(atogepant) receives MHRA marketing authorisation for the prevention of migraines in adults

    PRESS RELEASE - For UK consumer, trade and medical media only · The oral, once-daily calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) is licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain for the prophylaxis of migraine in adults who have at least four migraine days per month.[1] · The marketing authorisation is based on results from two pivotal Phase 3 studies in which the treatment demonstrated significant reduction in mean monthly migraine days from baseline across 12 weeks.[1-5] · The news closely follows the European

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe